Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthSpring Burosumab-twza Coverage Update | Open…
    Ask Trek AI about this page
    ModifiedHealthSpringPolicy RX502.058

    Burosumab-twza

    Customize your policy alerts

    Sign up for healthspring Policy RX502.058 alerts

    Get alerted when Policy RX502.058 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage considerations for burosumab-twza, including the requirement that the requested therapy be proven effective for the diagnosis and that the proposed dose, frequency, and duration align with an authoritative source. Member-specific benefit plans, contracts, and applicable state requirements control when they differ from this policy.

    Policy Summary
    PayerHealthSpring
    PolicyBurosumab-twza
    Policy CodePolicy RX502.058
    Change TypeModified — new conditional coverage criteria
    Effective DateN/A
    Next Review DateN/A
    Key ActionPrior authorization should establish that the member meets the applicable age, diagnosis, laboratory, clinical, renal-function, medication-discontinuation, and tumor-resectability requirements.
    SourceLink
    POLICY UPDATE CHANGES

    A new medical document establishes conditional medical-necessity coverage for burosumab-twza for X-linked hypophosphatemia and FGF23-related hypophosphatemia associated with phosphaturic mesenchymal tumors.

    The policy classifies burosumab-twza as experimental, investigational, and/or unproven when the stated coverage criteria are not met or for other non-FDA-approved indications.

    2Covered disease indications
    6 months+Minimum age for XLH
    2 years+Minimum age for TIO

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    <30 mL/min
    Renal function exclusion threshold
    1 weekXLH medication discontinuation
    2 weeksTIO medication discontinuation

    Coverage Criteria

    General Medical Necessity

    Coverage requires that the requested therapy be medically necessary and supported by current authoritative evidence.

    ALL of the following

    • The requested therapy is proven effective for the member's relevant diagnosis or procedure.
    • For drug therapy, the proposed dose, frequency, and duration are consistent with recommendations in at least one authoritative source, such as FDA-approved labeling, nationally recognized drug compendia, peer-reviewed literature, generally accepted standards of care, professional society guidelines, or applicable CMS coverage policy.

    Initial Therapy: X-Linked Hypophosphatemia

    Burosumab-twza (Crysvita) may be considered medically necessary for individuals 6 months of age and older with X-linked hypophosphatemia when ALL of the following are met:

    ALL of the following

    • Diagnosis of XLH is confirmed by ONE of the following

      • PHEX genetic testing confirms XLH.
      • Serum fibroblast growth factor 23 (FGF23) level is elevated.
    • Fasting serum phosphorus is below the normal range for the patient's age.
    • Clinical signs or symptoms of XLH are present, such as rickets, growth retardation, musculoskeletal pain, or bone fractures.
    • The member does not have severe renal impairment or end-stage renal disease, defined for this coverage criterion as a glomerular filtration rate below 30 mL/min.
    • Oral phosphate and active vitamin D analogs have been discontinued at least 1 week before initiation of burosumab-twza.

    Initial Therapy: Tumor-Induced Osteomalacia

    Burosumab-twza (Crysvita) may be considered medically necessary for individuals 2 years of age and older with FGF23-related hypophosphatemia in tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors when ALL of the following are met:

    ALL of the following

    • Tumor-induced osteomalacia is diagnosed and confirmed by an elevated serum fibroblast growth factor 23 (FGF23) level.
    • Fasting serum phosphorus is below the normal range for the patient's age.
    • The member does not have severe renal impairment or end-stage renal disease, defined for this coverage criterion as a glomerular filtration rate below 30 mL/min.
    • Oral phosphate and active vitamin D analogs have been discontinued at least 2 weeks before initiation of burosumab-twza.
    • The phosphaturic mesenchymal tumor cannot be curatively resected or localized.

    Therapy Interruption and Reassessment

    Treatment must be interrupted and reassessed when the underlying tumor is treated.

    ALL of the following

    • If the member undergoes treatment of the underlying tumor, including surgical excision or radiation therapy, burosumab-twza is interrupted after treatment is completed.
    • Serum phosphorus is reassessed after treatment of the underlying tumor.
    • If serum phosphorus remains below the lower limit of normal, burosumab-twza is restarted at the initiation dose; subsequent dose adjustment follows the FDA label to maintain serum phosphorus within the age-specific reference range.

    FDA-Labeled Indications

    Coverage is limited to FDA-labeled indications and labeled age groups.

    ONE of the following FDA-labeled indications

    • X-linked hypophosphatemia (XLH) in adult or pediatric patients 6 months of age and older.>= 6 months
    • FGF23-related hypophosphatemia in tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized, in adult or pediatric patients 2 years of age and older.>= 2 years

    Contraindication Screening

    Screen for all FDA-labeled contraindications and excluded clinical circumstances before initiation or continuation.

    ALL of the following must be absent

    • Severe renal impairment or end-stage renal disease.
    • Serum phosphorus within or above the normal range for the patient's age.
    • Concomitant use of oral phosphate or active vitamin D analogs.

    X-Linked Hypophosphatemia — Medical Necessity Coverage Pathway

    Coverage pathway for XLH:

    Coverage requires ALL of the following

    • The member is 6 months of age or older and has XLH.
    • The applicable XLH diagnostic, laboratory, clinical, renal, and medication-discontinuation criteria are met.

    Tumor-Induced Osteomalacia — Medical Necessity Coverage Pathway

    Coverage pathway for TIO:

    Coverage requires ALL of the following

    • The member is 2 years of age or older and has FGF23-related hypophosphatemia in tumor-induced osteomalacia associated with a phosphaturic mesenchymal tumor.
    • The applicable TIO diagnostic, laboratory, renal, medication-discontinuation, and tumor-resectability criteria are met.

    State regulations and the member contract must be reviewed. For members residing in Ohio, Ohio Revised Code § 3923.60 requires group or individual policies that cover prescription drugs to cover an FDA-approved drug when prescribed for a use recognized as safe and effective for the indication in an adopted standard medical reference compendium or in medical literature, even when the use is not FDA-approved. Medical-literature support requires safety and efficacy confirmed in two articles from major peer-reviewed professional medical journals. Evidence limited to case reports or case series is insufficient. Coverage is never required for an FDA-recognized contraindicated use or for non-formulary drugs.

    Burosumab-twza is excluded in members with severe renal impairment or end-stage renal disease. For this policy, severe renal impairment is defined as a glomerular filtration rate below 30 mL/min.

    Burosumab-twza is contraindicated when serum phosphorus is within or above the normal range for the patient's age because increases above the upper limit of normal may increase the risk of nephrocalcinosis.

    Burosumab-twza must not be used with oral phosphate or active vitamin D analogs. These therapies must be discontinued before initiation.

    Contraindicated concomitant therapies include oral phosphate and active vitamin D analogs, including calcitriol, paricalcitol, doxercalciferol, and calcifediol. The FDA recommends discontinuing these therapies 1 week before initiation.

    Crysvita is contraindicated when serum phosphorus is within or above the normal range for the patient's age. Dose interruption or reduction may be required based on serum phosphorus levels; patients with TIO who undergo treatment of the underlying tumor should have dosing interrupted and adjusted to prevent hyperphosphatemia.

    Crysvita is contraindicated in severe renal impairment or end-stage renal disease. For pediatric patients, this includes estimated GFR 15–29 mL/min/1.73 m² or end-stage renal disease (eGFR below 15 mL/min/1.73 m²). For adults, this includes creatinine clearance 15–29 mL/min or end-stage renal disease (creatinine clearance below 15 mL/min).

    Safety and effectiveness have not been established for XLH in pediatric patients below 6 months of age. Safety and effectiveness have not been established for TIO in pediatric patients below 2 years of age. Use below these labeled ages is not covered.

    Burosumab-twza is considered experimental, investigational, and/or unproven for all other non-FDA-approved indications.

    Burosumab-twza is considered experimental, investigational, and/or unproven when the applicable coverage criteria are not met or when it is requested for a non-FDA-approved indication.

    Coding and Coverage Parameters

    HCPCS CodesHCPCS
    J0584
    CPT CodesCPT
    No codes listed
    XLH minimum age
    Minimum age6 months of age and older
    IndicationX-linked hypophosphatemia
    Coverage statusMay be considered medically necessary when all applicable criteria are met
    TIO minimum age
    Minimum age2 years of age and older
    IndicationFGF23-related hypophosphatemia in tumor-induced osteomalacia
    Associated tumor

    Provider Actions and Authorization

    Prior Authorization

    Prior Authorization Required for Covered Indications

    Prior authorization is required for burosumab-twza (Crysvita) requests for covered indications. Submit documentation supporting the applicable diagnosis, age, laboratory findings, renal function, treatment history, and all coverage criteria.

    • Include records supporting XLH or FGF23-related hypophosphatemia in TIO, as applicable.
    • Document the requested indication, dose, frequency, and duration.
    Documentation Required

    All Coverage Criteria Must Be Met

    Coverage requires that all applicable medical-necessity criteria for the requested indication are met. Requests that do not satisfy the complete criteria may be denied.

    • XLH: patient is at least 6 months old and meets all listed XLH criteria.
    • TIO: patient is at least 2 years old and meets all listed TIO criteria.

    Policy Background

    This policy addresses coverage of burosumab-twza (Crysvita), a pharmacy and specialty-drug therapy. Coverage is tied to evidence that the therapy is effective for the relevant diagnosis and that the proposed dose, frequency, and duration are supported by an authoritative source. The covered indications are X-linked hypophosphatemia in individuals 6 months and older and FGF23-related hypophosphatemia in tumor-induced osteomalacia in individuals 2 years and older, when all applicable criteria are met.

    Definitions

    X-linked hypophosphatemia definition
    ConditionX-linked hypophosphatemia (XLH)
    CauseDominant disorder caused by mutations in the PHEX gene
    PathophysiologyExcessive FGF23 causes renal phosphate wasting
    Tumor-induced osteomalacia definition
    ConditionTumor-induced osteomalacia (TIO)
    NatureRare acquired paraneoplastic syndrome
    MechanismFGF23-secreting tumors produce renal phosphate wasting, hypophosphatemia, and osteomalacia

    Initial Therapy Criteria

    Initial Coverage Requirements

    Initial coverage requires both of the following general medical-necessity conditions:

    Initial coverage requirements

    • The requested burosumab-twza therapy must be proven effective for the relevant diagnosis.
    • The proposed dose, frequency, and duration must be supported by at least one authoritative source.

    Initial Therapy: XLH

    Covered when ALL of the following are met:

    XLH initial therapy

    • The member is at least 6 months old.Age >= 6 months

    Continuation and Reassessment

    Interruption After Tumor Treatment

    Treatment interruption is required after treatment of the underlying tumor:

    Post-treatment reassessment: When the underlying tumor is treated with surgical excision or radiation therapy, interrupt burosumab-twza and reassess serum phosphorus after completion of tumor treatment.Serum phosphorus reassessment after treatment

    Restart at the patient's initiation dose if serum phosphorus remains below the lower limit of normal; follow the FDA-labeled dose-adjustment schedule.

    Continuation and Monitoring

    Continue therapy with monitoring and dose adjustment according to the FDA label:

    Ongoing therapy monitoring

    • Continue treatment with appropriate fasting serum phosphorus monitoring and maintain serum phosphorus within the age-specific reference range.

    Site of Care and Administration

    Billing Rule

    Administer in the appropriate site of care

    Burosumab-twza is administered by subcutaneous injection and should be administered by a healthcare provider.

    Policy Summary
    PayerHealthSpring
    PolicyBurosumab-twza
    Policy CodePolicy RX502.058
    Change TypeModified — new conditional coverage criteria
    Effective DateN/A
    Next Review DateN/A
    Key ActionPrior authorization should establish that the member meets the applicable age, diagnosis, laboratory, clinical, renal-function, medication-discontinuation, and tumor-resectability requirements.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Coverage ParametersProvider Actions and AuthorizationPolicy BackgroundDefinitionsInitial Therapy CriteriaContinuation and ReassessmentSite of Care and Administration
    Phosphaturic mesenchymal tumor
    Severe renal impairment or ESRD
    General exclusion thresholdGlomerular filtration rate below 30 mL/min
    Pediatric severe impairmenteGFR 15 to 29 mL/min/1.73 m²
    Adult severe impairmentCreatinine clearance 15 to 29 mL/min
    XLH medication discontinuation
    TherapyXLH treatment initiation
    MedicationsOral phosphate and active vitamin D analogs
    Required intervalDiscontinued one week prior to initiation
    TIO medication discontinuation
    TherapyTIO treatment initiation
    MedicationsOral phosphate and active vitamin D analogs
    Required intervalDiscontinued two weeks prior to initiation
    Serum phosphorus
    SpecimenFasting serum phosphorus
    Required resultBelow the normal range for the patient's age
    ExclusionTreatment is contraindicated when serum phosphorus is within or above the age-specific normal range
    Pediatric XLH continued-treatment phosphorus target
    PopulationPediatric patients with XLH
    Target rangeAbove the lower limit of the age-specific reference range and below 5 mg/dL
    Monitoring intervalEvery 4 weeks for the first 3 months
    Study 1 pediatric XLH rickets severity threshold
    StudyStudy 1 pediatric XLH
    AssessmentRickets Severity Score (RSS)
    Severity thresholdRSS ≥ 2.0
    Pediatric Study 1 lower limit of normal serum phosphorus
    PopulationPediatric Study 1
    MeasureLower limit of normal serum phosphorus
    Value3.2 mg/dL
    Pediatric Study 2 target fasting serum phosphorus
    StudyPediatric Study 2
    MeasureFasting serum phosphorus
    Target3.5 to 5.0 mg/dL
    Substantial radiographic healing threshold
    AssessmentRadiographic Global Impression of Change (RGI-C)
    MeaningRadiographic evidence of substantial healing
    ThresholdRGI-C score ≥ +2.0
    Target fasting serum phosphorus for TIO studies
    PopulationTumor-induced osteomalacia studies
    MeasureFasting serum phosphorus
    Target2.5 to 4.0 mg/dL
    Study 6 lower limit of normal serum phosphorus
    StudyStudy 6
    MeasureLower limit of normal serum phosphorus
    Value2.5 mg/dL
    Documentation Required

    Diagnostic Confirmation Required

    Document diagnostic confirmation for the requested indication. XLH must be confirmed by a PHEX genetic test or an elevated serum fibroblast growth factor 23 level; TIO must be confirmed by an elevated serum fibroblast growth factor 23 level.

    • Specify whether the request is for XLH or FGF23-related hypophosphatemia associated with a phosphaturic mesenchymal tumor.
    • Attach relevant genetic, laboratory, pathology, or specialist documentation.
    Documentation Required

    Low Fasting Serum Phosphorus

    Document that fasting serum phosphorus is below the normal range for the patient’s age before treatment. This laboratory finding is required for both covered XLH and TIO requests.

    • Submit the baseline fasting serum phosphorus result and the applicable age-based reference range.
    Documentation Required

    XLH Clinical Manifestations

    For XLH requests, document clinical manifestations consistent with the disease, such as rickets, growth retardation, musculoskeletal pain, or bone fractures.

    • Describe the patient’s signs and symptoms and their clinical significance.
    Documentation Required

    Renal Function Documentation

    Document renal function and confirm that the patient does not have severe renal impairment or end-stage renal disease. Severe impairment is generally defined as a glomerular filtration rate below 30 mL/min for coverage purposes.

    • Submit the relevant GFR, eGFR, or creatinine-clearance result.
    • Do not request coverage for patients with severe renal impairment or end-stage renal disease.
    Documentation Required

    Required Medication Washout

    Document discontinuation of oral phosphate and active vitamin D analogs before burosumab-twza initiation. The required washout is one week for XLH and two weeks for TIO.

    • List the medications discontinued and the discontinuation date.
    • Active vitamin D analogs include agents such as calcitriol, paricalcitol, doxercalciferol, and calcifediol.
    Documentation Required

    TIO Tumor Status

    For TIO requests, document that the associated phosphaturic mesenchymal tumor cannot be curatively resected or localized.

    • Provide tumor-imaging, surgical, oncology, or specialist documentation supporting unresectability or inability to localize the tumor.
    Documentation Required

    Interrupt and Reassess After Tumor Treatment

    If the underlying TIO tumor is treated, including by surgical excision or radiation therapy, burosumab-twza treatment must be interrupted. Serum phosphorus must be reassessed after tumor treatment, and dosing should follow the FDA-labeled restart and adjustment instructions.

    • Document the tumor treatment and treatment-completion date.
    • Submit the post-treatment serum phosphorus result before resuming or adjusting therapy.
    Documentation Required

    Clinical and Laboratory Documentation

    Submit clinical and laboratory documentation supporting the requested indication and treatment. Records should establish the patient’s age, diagnosis, baseline fasting serum phosphorus, renal function, and required treatment status.

    • For XLH, include qualifying clinical signs and symptoms and diagnostic confirmation.
    • For TIO, include elevated FGF23, tumor status, and documentation that the tumor cannot be curatively resected or localized.
    • Include evidence that oral phosphate and active vitamin D analogs were discontinued for the required washout period.
    Documentation Required

    Tumor Treatment Documentation

    For TIO, document treatment of the underlying tumor when applicable, including surgery or radiation therapy. Burosumab-twza must be interrupted during this transition and serum phosphorus reassessed after treatment is completed.

    • Provide operative, radiation, oncology, or specialist records.
    • Document whether therapy was interrupted and the post-treatment phosphorus result.
    • Restart at the initiation dose only if serum phosphorus remains below the lower limit of normal; otherwise follow FDA-labeled dose adjustment.

    Unsupported block type: denial_risk

    Billing Rule

    Ohio Contraindicated or Non-Formulary Use

    For members residing in Ohio, coverage exceptions must be evaluated under applicable state requirements and the member contract. Coverage is not required for an FDA-recognized contraindicated use or for non-formulary drugs.

    • Off-label coverage may require support from accepted compendia or two qualifying major peer-reviewed medical journal articles demonstrating safety and efficacy.
    • Case reports or case series alone are insufficient under the cited Ohio standard.
    Denial Risk

    Failure to Meet Coverage Criteria

    Burosumab-twza is considered experimental, investigational, and/or unproven when the applicable XLH or TIO criteria are not met. Requests for other non-FDA-approved indications may also be denied.

    • Confirm that the requested indication is covered and that every applicable criterion is documented.
    • Do not submit a covered-indication request without supporting diagnostic, laboratory, renal, and treatment records.
    Denial Risk

    Severe Renal Impairment or ESRD

    Do not use burosumab-twza in patients with severe renal impairment or end-stage renal disease. For coverage purposes, severe renal impairment is generally a GFR below 30 mL/min.

    • The FDA labeling identifies severe renal impairment as pediatric eGFR 15–29 mL/min/1.73 m² or adult creatinine clearance 15–29 mL/min; end-stage renal disease is pediatric eGFR below 15 mL/min/1.73 m² or adult creatinine clearance below 15 mL/min.
    • Submit current renal-function results with the authorization request.
    Denial Risk

    Inappropriate Phosphorus Level or Concomitant Therapy

    Burosumab-twza must not be used when serum phosphorus is within or above the normal range for the patient’s age or concurrently with oral phosphate or active vitamin D analogs.

    • Confirm that baseline serum phosphorus is below the age-specific normal range.
    • Document discontinuation of oral phosphate and active vitamin D analogs before initiation.
    • Concomitant use may cause hyperphosphatemia and nephrocalcinosis.
    Denial Risk

    Contraindicated Use

    Crysvita is contraindicated with oral phosphate or active vitamin D analogs, when serum phosphorus is within or above the normal range for age, and in severe renal impairment or end-stage renal disease.

    • Do not authorize or administer concomitant oral phosphate or active vitamin D analogs.
    • Verify age-appropriate phosphorus levels before initiation and during therapy.
    • Verify renal function and exclude severe impairment or end-stage renal disease.
    Denial Risk

    Use Below Labeled Age

    Use below the labeled age is not supported. Crysvita is labeled for XLH in patients 6 months of age and older and for TIO in patients 2 years of age and older.

    • XLH below 6 months: safety and effectiveness have not been established.
    • TIO below 2 years: safety and effectiveness have not been established.
    Denial Risk

    Criteria Not Met or Non-Approved Indication

    Coverage is available only when the applicable criteria are met for an FDA-approved indication. Criteria not met, or use for another non-approved indication, is considered experimental, investigational, and/or unproven and may be denied.

    • Confirm the diagnosis, age threshold, laboratory findings, renal status, medication washout, and any required tumor documentation.
    • Apply the denial rule when the requested use is outside the covered XLH or TIO indications.
    Phosphaturic mesenchymal tumor definition
    Tumor typePhosphaturic mesenchymal tumor
    Associated factorFGF23 secretion
    Associated conditionTumor-induced osteomalacia
    FGF23 definition and mechanism
    Full nameFibroblast growth factor 23
    Physiologic effectSuppresses renal tubular phosphate reabsorption
    Treatment mechanismBurosumab-twza binds to and inhibits its biological activity
    TIO associated with unresectable or unlocalized tumor
    ConditionTumor-induced osteomalacia with FGF23-related hypophosphatemia
    Tumor statusPhosphaturic mesenchymal tumor cannot be curatively resected or localized
    Covered agePediatric and adult patients 2 years of age and older
    Pediatric severe renal impairment or ESRD definition
    PopulationPediatric patients
    Severe renal impairmenteGFR 15 to 29 mL/min/1.73 m²
    End-stage renal diseaseeGFR below 15 mL/min/1.73 m²
    Adult severe renal impairment or ESRD definition
    PopulationAdult patients
    Severe renal impairmentCreatinine clearance 15 to 29 mL/min
    End-stage renal diseaseCreatinine clearance below 15 mL/min
    Radiographic Global Impression of Change definition
    AssessmentRadiographic Global Impression of Change (RGI-C)
    MethodSide-by-side comparison of wrist and knee radiographs from two timepoints
    InterpretationHigher scores indicate greater improvement; +2.0 represents substantial radiographic healing
    Rickets Severity Score definition
    AssessmentRickets Severity Score (RSS)
    Scale10-point score
    MethodAssigned from wrist and knee radiographs at a single timepoint; higher scores indicate greater severity
    Osteomalacia-related fracture definition
    FindingOsteomalacia-related fracture
    CauseAtraumatic lucency
    ExtentExtends across both bone cortices
    Pseudofracture definition
    FindingPseudofracture
    CauseAtraumatic lucency
    ExtentExtends across one bone cortex
    Lower limit of normal serum phosphorus — Study 1
    StudyPediatric Study 1
    MeasureLower limit of normal serum phosphorus
    Value3.2 mg/dL
    LLN — Study 6 serum phosphorus
    StudyStudy 6
    AbbreviationLLN means lower limit of normal
    Value2.5 mg/dL
    XLH diagnostic definition
    ConditionX-linked hypophosphatemia
    Diagnostic basisClinical evaluation, laboratory findings confirming renal phosphate wasting after exclusion of mimicking conditions, and skeletal imaging
    Confirmatory testingPathogenic or likely pathogenic PHEX variants are confirmatory
    Tumor-induced osteomalacia associated with FGF23-related hypophosphatemia
    ConditionTumor-induced osteomalacia
    Biochemical basisFGF23-related hypophosphatemia
    Tumor statusUnderlying tumor is not amenable to surgical excision or cannot be located
  1. Diagnostic confirmation

    • XLH is confirmed by a PHEX genetic test.
    • XLH is confirmed by an elevated serum fibroblast growth factor 23 level.
  2. Fasting serum phosphorus is below the normal range for the patient's age.
  3. Clinical signs or symptoms of XLH are present.

    Examples include rickets, growth retardation, musculoskeletal pain, or bone fractures.

  4. Severe renal impairment and end-stage renal disease are absent.GFR >= 30 mL/min
  5. Oral phosphate and active vitamin D analogs were discontinued one week before initiation.Discontinued 1 week before initiation
  6. Initial Therapy: TIO

    Covered when ALL of the following are met:

    TIO initial therapy

    • The member is at least 2 years old.Age >= 2 years
    • TIO is confirmed by an elevated serum fibroblast growth factor 23 level.
    • Fasting serum phosphorus is below the normal range for the patient's age.
    • Severe renal impairment and end-stage renal disease are absent.GFR >= 30 mL/min
    • Oral phosphate and active vitamin D analogs were discontinued two weeks before initiation.Discontinued 2 weeks before initiation
    • The tumor cannot be curatively resected or localized.

    Initial Therapy Eligibility

    Initiation should follow a labeled indication and contraindication screening:

    Initial treatment eligibility

    • Labeled indication

      • The patient has XLH and is 6 months of age or older.XLH: >= 6 months
      • The patient has FGF23-related hypophosphatemia in TIO associated with a phosphaturic mesenchymal tumor that cannot be curatively resected or localized and is 2 years of age or older.TIO: >= 2 years
    • Serum phosphorus is below the normal range for age.
    • Oral phosphate and active vitamin D analogs have been discontinued one week before initiation.Discontinued 1 week before initiation
    • The patient does not have severe renal impairment or end-stage renal disease.Pediatric eGFR or adult creatinine clearance >= 30 mL/min

    Initial Therapy

    Burosumab-twza may be considered medically necessary for initial treatment when all applicable coverage criteria are met:

    Covered indications

    • The individual has X-linked hypophosphatemia and is 6 months of age or older.Age >= 6 months
    • The individual has FGF23-related hypophosphatemia in tumor-induced osteomalacia associated with a phosphaturic mesenchymal tumor and is 2 years of age or older.Age >= 2 years
  7. For pediatric patients with XLH, measure fasting serum phosphorus every 4 weeks for the first 3 months; thereafter monitor as appropriate.Every 4 weeks for first 3 months
  8. For adult patients with XLH and pediatric or adult patients with TIO, assess fasting serum phosphorus monthly for the first 3 months, measured 2 weeks post-dose; thereafter monitor as appropriate.Monthly for first 3 months; 2 weeks post-dose
  9. Follow the FDA-labeled dose-adjustment schedule to maintain serum phosphorus within the reference range for age.